A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells

Biochemical Pharmacology

Volumn 68, Issue 2, 2004, Pages 293-303

  Juang, Shin Hun ^a   Pan, Wen Yu ^a   Kuo, Ching Chuan ^a   Liou, Jing Ping ^b   Hung, Yi Mei ^a   Chen, Li Tzong ^a   Hsieh, Hsing Pang ^b   Chang, Jang Yang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

2,5 bis (4 hydroxy 3 methoxybenzylidene) cyclopentanone; 3,3 Dihexyloxacarbocyanine iodide; BPR0Y007; DiOC 6(3); DNA topoisomerase I; mitochondrial potential transition; MPT; PBS; phosphate buffered saline; PI; propidium iodide; Top 1

Indexed keywords

2,5 BIS(4 HYDROXY 3 METHOXYBENZYLIDENE)CYCLOPENTANONE; BENZYLIDENE DERIVATIVE; BPR 0Y007; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CYCLOPENTANONE DERIVATIVE; DNA FRAGMENT; FAS ANTIGEN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DEATH; CELL STRAIN KB; CYTOTOXICITY; DNA DETERMINATION; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLIDENE COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FAS LIGAND PROTEIN; G2 PHASE; HUMANS; KB CELLS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; MITOSIS; PENTANONES; PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 2942573028     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.03.036     Document Type: Article

References (36)

1. Chang J.Y., Hsieh H.P., Pan W.Y., Liou J.P., Bey S.J., Chen L.T., et al. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. Biochem. Pharmacol. 65:2003;2009-2019
2. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 68:1999;383-424
3. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell. Dev. Biol. 5:1999;269-290
4. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Woo M., Soengas M.S., et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 94:1998;339-352
5. Sun X.M., MacFarlane M., Zhuang J., Wolf B.B., Green D.R., Cohen G.M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem. 274:1999;5053-5060
6. Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M., Krammer P.H., et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16:1997;2794-2804
7. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312
8. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542
9. Sardjiman S.S., Reksohadiprodjo M.S., Hakim L., van der Good H., Timmerman H. 1, 5-Diphenyl-1, 4-pentadiene-3-ones an cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur. J. Med. Chem. 32:2003;625-630
10. Finlay G.J., Baguley B.C., Wilson W.R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem. 139:1984;272-277
11. Grutter M.G. Caspases: key players in programmed cell death. Curr. Opin. Struct. Biol. 10:2000;649-655
12. Patel T., Gores G.J., Kaufmann S.H. The role of proteases during apoptosis. FASEB J. 10:1996;587-597
13. Tian R., Zhang G.Y., Yan C.H., Dai Y.R. Involvement of poly(ADP-ribose) polymerase and activation of caspase-3-like protease in heat shock-induced apoptosis in tobacco suspension cells. FEBS Lett. 474:2000;11-15
14. Ferreira C.G., Span S.W., Peters G.J., Kruyt F.A., Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 60:2000;7133-7141
15. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., Reed J.C. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53:1993;4701-4714
16. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:1997;479-489
17. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 85:1996;803-815
18. Muzio M., Salvesen G.S., Dixit V.M. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J. Biol. Chem. 272:1997;2952-2956
19. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:1996;574-577
20. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K.M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:1997;3823-3829
21. Muller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin. Invest. 99:1997;403-413
22. Kidd V.J. Proteolytic activities that mediate apoptosis. Annu. Rev. Physiol. 60:1998;533-573
23. Kaufmann S.H. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta. 1400:1998;195-211
24. Shimizu T., Pommier Y. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia. 11:1997;1238-1244
25. Tahir S.K., Han E.K., Credo B., Jae H.S., Pietenpol J.A., Scatena C.D., et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 61:2001;5480-5485
26. Blagosklonny M.V., Giannakakou P., el Deiry W.S., Kingston D.G., Higgs P.I., Neckers L., et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 57:1997;130-135
27. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 92:1995;4507-4511
28. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255
29. Jiang J.D., Davis A.S., Middleton K., Ling Y.H., Perez-Soler R., Holland J.F., et al. 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. Cancer Res. 58:1998;5389-5395
30. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., Nesterova M., Cho-Chung Y.S., Longo D.L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell Biol. 18:1998;3509-3517
31. Tahir S.K., Han E.K., Credo B., Jae H.S., Pietenpol J.A., Scatena C.D., et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 61:2001;5480-5485
32. Wang L.G., Liu X.M., Kreis W., Budman D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 44:1999;355-361
33. Yamamoto K., Ichijo H., Korsmeyer S.J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 19:1999;8469-8478
34. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817-827
35. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188:1998;2033-2045
36. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15:1995;3032-3040